PRIM, S.A. AI Stock Analysis
Want to see ES:PRM full AI Analyst Report?
PRIM, S.A. (PRM) AI Stock Analysis
PRIM, S.A.
(BME:PRM)
Robust financial stability with debt elimination and profit growth drives the score, supported by positive technical uptrend and attractive valuation; cash flow volatility is a minor drag.
PRIM, S.A. (PRM) vs. iShares MSCI Spain ETF (EWP)
- Market Cap
- EUR 207.62M
- Dividend Yield
- 4.11%
- Average Volume (3M)
- 3,393
- Price to Earnings (P/E)
- 16.2
- Beta (1Y)
- 0.25
- Revenue Growth
- 4.20%
- EPS Growth
- -10.44%
- Country
- Spain
- Employees
- 959
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
PRIM, S.A. Business Overview & Revenue Model
Company Description
Prim, S.A., operating through its various affiliated entities, specializes in the conception, production, and sale of orthopedic solutions. These items are utilized across diverse fields such as physical therapy, aquatic therapies (like thalassothera...
How the Company Makes Money
PRIM, S.A. makes money primarily by selling healthcare and medical-technology products to professional and institutional customers (e.g., hospitals, clinics, pharmacies, orthopedic and rehabilitation centers) as well as through retail channels where...
PRIM, S.A. Financial Statement Overview
Summary
Strong balance sheet with zero debt and growing equity, steady revenue and profit growth in income statement, but mixed cash flows with volatility in free cash flow.
Income Statement
75PositiveBalance Sheet
85Very PositiveCash Flow
65Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 250.65M | 251.82M | 233.15M | 216.51M | 197.25M | 168.51M |
| Gross Profit | 124.50M | 127.01M | 112.62M | 45.30M | 94.56M | 83.08M |
| EBITDA | 29.07M | 33.94M | 26.23M | 28.05M | 19.71M | 30.09M |
| Net Income | 13.03M | 16.68M | 10.92M | 12.67M | 8.39M | 17.42M |
Balance Sheet | ||||||
| Total Assets | 209.04M | 196.53M | 190.28M | 200.10M | 184.99M | 179.85M |
| Cash, Cash Equivalents and Short-Term Investments | 25.42M | 23.03M | 13.75M | 13.25M | 14.94M | 36.54M |
| Total Debt | 14.89M | 16.28M | 18.50M | 25.48M | 22.07M | 19.07M |
| Total Liabilities | 71.50M | 58.89M | 61.34M | 74.28M | 65.28M | 58.38M |
| Stockholders Equity | 137.54M | 137.64M | 128.93M | 125.82M | 119.71M | 121.47M |
Cash Flow | ||||||
| Free Cash Flow | 23.44M | 18.14M | 10.76M | -20.09M | -7.02M | 13.87M |
| Operating Cash Flow | 36.74M | 30.46M | 22.11M | -11.33M | 4.89M | 26.30M |
| Investing Cash Flow | -11.06M | -10.07M | -7.59M | -3.67M | -14.10M | -8.70M |
| Financing Cash Flow | -13.43M | -11.62M | -11.32M | 10.46M | -12.19M | -15.09M |
PRIM, S.A. Peers Comparison
Overall Rating
ES:PRM80Outperform
ES:PHM67Neutral
ES:ORY44Neutral
ES:ATRY41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | EUR 207.62M | 16.15 | 9.47% | 4.11% | 4.20% | -10.44% | |
| 67Neutral | EUR 1.05B | 14.90 | 27.64% | 1.69% | 32.42% | 103.06% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | EUR 202.76M | -47.30 | -3.79% | ― | ― | -24.82% | |
| 41Neutral | EUR 193.75M | -1.99 | -65.08% | ― | -53.44% | -296.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ES:PRM | PRIM, S.A. | 12.25 | -0.58 | -4.50% | |
| ES:ORY | Oryzon Genomics | 2.47 | -0.49 | -16.56% | |
| ES:PHM | Pharma Mar SA | 59.20 | -15.54 | -20.79% | |
| ES:ATRY | Atrys Health SA | 2.55 | -0.10 | -3.77% | |
| ES:LAB | Labiana Health SA | 4.80 | 0.29 | 6.36% | |
| ES:STNA | Santa Ana Global Enterprises SA | 15.40 | 1.80 | 13.24% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 04, 2026
